HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Townsend, R. R. PubMed PubMed Citation Articles by Townsend, R. R.

Stroke in Chronic Kidney Disease: Prevention and Management

Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania

Correspondence: Dr. Raymond Townsend, University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104. Phone: 215-662-4630; Fax: 215-662-3459; E-mail: townsend{at}mail.med.upenn.edu

The incidence of stroke is elevated among individuals with kidney disease. Traditional risk factors seem to account for much but not all of this excess risk. Blood pressure control is the most important aspect of stroke prevention. Multiple classes of antihypertensive agents, including diuretics, calcium channel blockers, angiotensin-converting enzyme inhibitors, and angiotensin II receptor blockers, have reduced stroke risk. Some physiologic and clinical evidence suggests that angiotensin II receptor blockers may offer superior benefit to that of angiotensin-converting enzyme inhibitors for the same level of blood pressure control; however, few head-to-head trials have compared these two agent classes directly using stroke as an outcome.